GlassScriptPhysician profile
Kevin Schesing
NPI 1356872220
$4,009.84
in general payments reported to CMS, 2019-2025
14 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $362 · 2021: $1,091 · 2022: $1,016 · 2023: $579 · 2024: $598 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,401.09 | 2020-2023 | Andexxa, Lokelma, Farxiga |
| Heartflow, INC. | $610.96 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $569.69 | 2020-2023 | Xarelto |
| Amgen INC. | $260.50 | 2022-2023 | Repatha |
| Medtronic, INC. | $234.28 | 2024-2025 | Corevalve Evolut R, Symplicity G3 |
| Siemens Medical Solutions USA, INC. | $182.91 | 2023 | Naeotom Alpha |
| Baxter Healthcare | $175.88 | 2022 | |
| Boston Scientific Corporation | $150.74 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $121.44 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.90 | 2020 | |
| Lantheus Medical Imaging, INC. | $67.72 | 2021 | |
| Biotronik INC. | $54.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.12 | 2020-2022 | |
| Philips North America LLC | $21.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schesing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.